Wunderlich G, del Portillo H A
Departamento de Parasitologia, Universidade de São Paulo, Brazil.
Mol Med. 2000 Mar;6(3):238-45.
Mammalian cells expressing the small hepatitis B virus surface protein (HBs) secrete highly immunogenic 20 nm lipoprotein particles. Previous studies demonstrated that the fusion of foreign sequences into certain regions of HBs leads to chimeric particles carrying epitopes for the foreign peptide, as well as for HBs. The present study investigates immunologic and biochemical properties of the fusion of the C-terminal region of the merozoite surface 1 protein of P. vivax, the most widely distributed human malaria parasite, and HBs (PvMSP1(19)-HBs).
COS7 cells were transfected with a plasmid coding for PvMSP1(19)-HBs. The hybrid products were analyzed by density gradient centrifugation and electron microscopy or detected by metabolic labeling and immunoprecipitation with anti-HBs and patient-derived anti-P. vivax serum. Mice were immunized with the vector and the antibody response was checked by ELISA.
The fusion PvMSP1(19)-HBs formed particles of 20-45 nm size, which were secreted from COS7 cells. The particles were immunoprecipitable with anti-HBs and serum of different P. vivax-positive individuals. Immunization of mice with the construct as a genetic vaccine showed that antibodies were raised mostly against the PvMSP1(19) domain and recognized the native protein.
Due to its biochemical and antigenic properties, the hybrid particle will be useful in future vaccine trials against the asexual blood stages of P. vivax as a genetic and/or a proteic subunit candidate.
表达乙肝病毒小表面蛋白(HBs)的哺乳动物细胞分泌高度免疫原性的20纳米脂蛋白颗粒。先前的研究表明,将外源序列融合到HBs的特定区域会导致嵌合颗粒携带外源肽以及HBs的表位。本研究调查了间日疟原虫(最广泛分布的人类疟原虫)裂殖子表面蛋白1(PvMSP1)C末端区域与HBs融合体(PvMSP1(19)-HBs)的免疫学和生化特性。
用编码PvMSP1(19)-HBs的质粒转染COS7细胞。通过密度梯度离心和电子显微镜分析杂交产物,或通过代谢标记以及用抗HBs和患者来源的抗间日疟原虫血清进行免疫沉淀来检测。用该载体免疫小鼠,并通过ELISA检查抗体反应。
融合体PvMSP1(19)-HBs形成了大小为20 - 45纳米的颗粒,这些颗粒从COS7细胞中分泌出来。这些颗粒可被抗HBs和不同间日疟原虫阳性个体的血清免疫沉淀。用该构建体作为基因疫苗免疫小鼠表明,产生的抗体主要针对PvMSP1(19)结构域并能识别天然蛋白。
由于其生化和抗原特性,这种杂交颗粒作为基因和/或蛋白亚基候选物,将在未来针对间日疟原虫无性血液阶段的疫苗试验中发挥作用。